Mechanisms of Action and Clinical Development of Elotuzumab.

15 An interim overall survival (OS) analysis demonstrated a strong trend in favor of ELd (HR 0.77; 95% CI 0.61, 0.97; P = 0.0257), in which there was a clear separation in the tail end of the Kaplan–Meier curves ( Figure 5 ). 15 Median (95% CI) OS was 43.7 months (40.3, not estimable (NE)) in the ELd arm and 39.6 months (33.3, NE) in the Ld arm. 15 The 4‐year PFS data

also in 5,725 other papers